Kymera Investor Presentation Deck

Percent Change from Baseline IRAK4 PK/PD Correlation in Blood (Plasma/Monocytes) (FLOW) 13 ng/mL threshold -20 -40 -60 -80 KT-474 Plasma PK and IRAK4 Degradation in HS and AD Patients Dosed for 28 Days are Comparable to HV High KT-474 Exposure in HS and AD Patients Skin -100 MAD PART C 0 4 8 12 16 20 24 28 32 36 40 KT-474 Ctrough/ng/mL KT-474 concentrations in plasma lead to same level of IRAK4 degradation in HV (n=48) and HS/AD (n=20) patients Concentrations above 3 ng/mL lead to same level of degradation (>80%) in HV and Patients IRAK4 Levels in Blood (PBMC) in Patients at Day 28 (MS) KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. Mean (± SE) Absolute IRAK4 Levels by MS [fmol/µg protein] 1.00 0.75 0.50 0.25 0.00 I Day 28 HS and AD Patients IRAK4 Levels at Day 28 (n=4) near LLOQ protein) Mean (+SE) IRAK4 Levels in Skin (fmol/µg N Mean 400 0.0 Mean (± SE) KT-474 Concentrations [ng/mL for Plasma, ng/g for Skin] 300 0 Reduced IRAK4 in Skin Lesions of AD and HS Patients 0.3 Plasma Day 28 Skin Day 28 MAD Healthy Subjects (Baseline) 46 0.12 ▬▬▬▬▬▬▬▬▬▬‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒‒ H AD Patients HS Patients AD Patients (Baseline) (Baseline) (Day 28) 7 0.22 + 11 0.24 6 IRAK4 Patients 0.1 HS Patients (Day 28) 9 0.11 PAGE 12

View entire presentation